Safety and Immunogenicity of a Delayed Heterologous Avian Influenza A(H7N9) Vaccine Boost Following Different Priming Regimens: A Randomized Clinical Trial
Authors:
- 19 July 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 229 (2) , 327-340
Abstract
Background: Influenza A (H7N9) has caused multiple disease waves with evidence of strain diversification. Optimal influenza A (H7N9) prime-boost vaccine strategies are unknown. Methods: We recruited participants who had received monovalent inactivated A/Shanghai/2/2013 (H7N9) vaccine (MIV) approximately 5 years earlier, as follows: MIV with MF59 (MF59 × 2 group), MIV with AS03 (AS03 × 2 group), unadjuvanted MIV (No Adj group), MIV with MF59 or AS03 followed by unadjuvanted MIV (Adjx1 group), and A/H7-naive (unprimed group). Participants were randomized to receive 1 dose of AS03-adjuvanted or unadjuvanted A/Hong Kong/125/2017 (H7N9) MIV and were followed for safety and immunogenicity using hemagglutination inhibition (HAI) and neutralizing antibody assays. Results: We enrolled 304 participants: 153 received the adjuvanted boost and 151 received the unadjuvanted boost. At 21 days postvaccination, the proportion of participants with HAI antibody titers against the boosting vaccine strain of ≥40 in the adjuvanted and unadjuvanted arms, respectively, were 88% and 49% in MF59 × 2 group, 89% and 75% in AS03 × 2 group, 59% and 20% in No Adj group, 94% and 55% in Adjx1group, and 9% and 11% in unprimed group. Conclusions: Serologic responses to a heterologous A(H7N9) MIV boost were highest in participants primed and boosted with adjuvant-containing regimens. Clinical Trials Registration: NCT03738241.Keywords
Funding Information
- Division of Microbiology and Infectious Diseases
- National Institutes of Health (HHSN272201300015I, HHSN272201300018I, HHSN272201300021I, HHSN272201300020I, HHSN272201300019I, HHSN272201300016I, HHSN272201300023I, HHSN272201300022I, 75N93021C00012)
- Institute for Clinical and Translational Research, University of Maryland, Baltimore;
- National Center for Advancing Translational Sciences (1UL1TR003098)
- General Clinical Research Center, University of Maryland
- Department of Health and Human Services
- Administration for Strategic Preparedness and Response
- Biomedical Advanced Research and Development Authority (HHSO100201600006I, HHSO1002012000131I, HHSO100201600004I)
- Sanofi Pasteur
- GSK
This publication has 25 references indexed in Scilit:
- Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune ResponseJAMA, 2015
- Serological Responses to an Avian Influenza A/H7N9 Vaccine Mixed at the Point-of-Use With MF59 AdjuvantJAMA, 2014
- Immunogenicity of Avian Influenza A/Anhui/01/2005(H5N1) Vaccine With MF59 AdjuvantJAMA, 2014
- Heterologous Prime-Boost Vaccination with MF59-Adjuvanted H5 Vaccines Promotes Antibody Affinity Maturation towards the Hemagglutinin HA1 Domain and Broad H5N1 Cross-Clade NeutralizationPLOS ONE, 2014
- Long-term booster schedules with AS03A-adjuvanted heterologous H5N1 vaccines induces rapid and broad immune responses in Asian adultsBMC Infectious Diseases, 2014
- Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: Homologous or heterologous booster response following two dose or single dose primingVaccine, 2012
- Qualification of the Hemagglutination Inhibition Assay in Support of Pandemic Influenza Vaccine LicensureClinical and Vaccine Immunology, 2009
- Antigenically Distinct MF59-Adjuvanted Vaccine to Boost Immunity to H5N1New England Journal of Medicine, 2008
- Detecting Human-to-Human Transmission of Avian Influenza A (H5N1)Emerging Infectious Diseases, 2007
- Interpretation of responses and protective levels of antibody against attenuated influenza A viruses using single radial haemolysisEpidemiology and Infection, 1984